Human variability and noncancer risk assessment - An analysis of the default uncertainty factor

被引:189
作者
Renwick, AG
Lazarus, NR
机构
[1] Univ Southampton, Clin Pharmacol Grp, Southampton SO16 7PX, Hants, England
[2] Open Univ, SE Reg, E Grinstead AH19 1ES, W Sussex, England
关键词
uncertainty factor; human variability; toxicokinetics; toxicodynamics; interindividual differences;
D O I
10.1006/rtph.1997.1195
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A 10-fold uncertainty factor is used for noncancer risk assessments to allow for possible interindividual differences between humans in the fate of the chemical in the body (kinetics) and target organ sensitivity (dynamics). Analysis of a database on the variability in each of these aspects is consistent with an even subdivision of the 10-fold factor into 10(0.5) (3.16) for kinetics and 10(0.5) (3.16) for dynamics. Analysis of the number of subjects in a normally and log-normally distributed population which would not be covered by factors of 3.16 supports this subdivision and also the use of a 10-fold factor to allow for both aspects. Analysis of kinetic data for subgroups of the population indicates that the standard default value of 3.16 for kinetics will not be adequate for all routes of elimination and all groups of the population. A scheme is proposed which would allow the selection of appropriate default uncertainty factors based on knowledge of the biological fate and effects of the chemical under review. (C) 1998 Academic Press.
引用
收藏
页码:3 / 20
页数:18
相关论文
共 142 条
[2]   THE INFLUENCES OF DOSE AND ETHNIC-ORIGINS ON THE PHARMACOKINETICS OF NIFEDIPINE [J].
AHSAN, CH ;
RENWICK, AG ;
WALLER, DG ;
CHALLENOR, VF ;
GEORGE, CF ;
AMANULLAH, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :329-338
[3]   DISPOSITION KINETICS OF METRONIDAZOLE IN CHILDREN [J].
AMON, I ;
AMON, K ;
SCHARP, H ;
FRANKE, G ;
NAGEL, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (01) :113-119
[4]  
[Anonymous], 1987, ENV HLTH CRIT
[5]  
[Anonymous], [No title captured]
[6]  
[Anonymous], 1994, ASS HUM HLTH RISKS C
[7]   PHARMACOKINETICS AND PHARMACODYNAMICS OF MK-383, A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB/IIIA RECEPTOR ANTAGONIST, IN HEALTHY-MEN [J].
BARRETT, JS ;
MURPHY, G ;
PEERLINCK, K ;
LEPELEIRE, ID ;
GOULD, RJ ;
PANEBIANCO, D ;
HAND, E ;
DECKMYN, H ;
VERMYLEN, J ;
ARNOUT, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) :377-388
[8]   CLINICAL PHARMACOKINETICS OF METOCLOPRAMIDE [J].
BATEMAN, DN .
CLINICAL PHARMACOKINETICS, 1983, 8 (06) :523-529
[9]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[10]  
BLACKWELL CP, 1989, EJC SUPPL, V25, P21